+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharma R&D Outsourcing Market - Global Outlook & Forecast 2022-2027

  • PDF Icon


  • 357 Pages
  • September 2022
  • Region: Global
  • Arizton
  • ID: 5661145
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

In a world of exponentially growing information, increasingly sophisticated technology, and an unstable economic environment, pharmaceutical corporations are increasingly outsourcing research efforts to academia and private contract research organizations (CROs). The pharmaceutical R&D outsourcing market is expected to grow as pharmaceutical and biotechnology companies spend more on outsourced services. Outsourced R&D activities span basic research through late-stage development, including genetic engineering, target identification, target validation, assay creation, hit discovery and lead optimization (hit candidates-as-a-service), safety and efficacy assessments in animal studies, and human clinical trials.


Paradigm Shift Towards Virtual Clinical Trials

  • Virtual clinical trials or decentralized clinical trials can bring significant digital changes to clinical research methods and enhance the patient-centric ecosystem. These solutions include countless benefits such as technology, advanced applications, electronic devices, online social engagement platforms, artificial intelligence (AI), robotic process automation, and machine learning (ML).
  • Patient recruitment is the most prominent cause of clinical delay, followed by significant patient absenteeism. Approximately 30% of phase 3 study discontinuances are said to be due to difficulty recruiting patients. These delays can cost pharmaceutical companies/sponsors up to USD 8 million daily. However, a complete digital or cross model of patient enrolment is employed in decentralized clinical trials. This helps reach the recruitment target easily and rapidly, making the entire process easy, and engaging.

The Emergence of Artificial intelligence (AI) in Drug Discovery & Development

  • Artificial intelligence (AI) is used in numerous areas across the world. In healthcare, especially in the pharmaceutical industry, AI is making a notable change as it has varied uses in drug discovery & development, clinical trials, and pharmaceutical productivity. The life cycle of a new drug from a lab to a store is a chain of many complex events that take time and development. Such difficult circumstances can be minimized with the help of AI, and the target can be achieved in a short time.
  • Many pharmaceutical companies implement innovative technologies such as AI and machine learning to achieve high-quality results in a short amount of time. In pharmaceutical product development, AI can manage the drug designing, decision making, and therapy determination for patients with personalized medicines; the generated clinical data can be stored for future drug development.
  • Global key players from the pharma and biotech industry, such as Eli Lilly Amgen, Merck, LEO, AstraZeneca, Bayer, Novartis, J&J, and BASF, are now a part of machine learning for pharmaceutical discovery.

Increasing Collaboration and partnership among CROs and Stakeholders of the Pharmaceutical Ecosystem

  • New models are emerging, and the first innovation comes from the Clinical Research Organization (CRO). CROs establish early chemical / biological entry points for the disease, approach potential interested companies, and collaborate on integrated drug discovery projects that they have identified. Strategic partnerships have long been an essential feature of the pharmaceutical industry. Numerous in-licenses, out-licenses, joint research, and joint development agreements exist between biopharmaceutical companies and academic research institutes.
  • In recent years, several significant outsourcing partnerships were done, such as the UK-based AstraZeneca partnering with academic organizations, the Cambridge University, focusing on drug development. It partnered with the University of Texas MD Anderson Cancer Center in the United States to develop immunotherapy.

Some of the examples of significant strategic partnerships of outsourcing are:

a) Allied Minds & Bristol-Myers Squibb

b) GSK & University of Leicester

c) Actelion Pharmaceuticals & Enamine


The pharma R&D outsourcing market is segmented on the product, stage of development, size of companies, therapy areas, and geography.

Insights by Product

Among all products, the small molecules segment reported a significant pharma R&D outsourcing market share. The small molecules segment is estimated to be higher because small molecules are likely to play a crucial part in easing the burden of chronic disease. This diverse group of small chemical compounds offers many benefits for scientists and researchers:

a) They have a wide-ranging use.
b) They are comparatively low in cost.
c) They allow for easy administration, including an oral route of administration.
d) They can pass within cell membranes to achieve their targets due to their small size.
e) They provide consistent results.

Pharmaceutical companies planning small molecule clinical studies need to work with the appropriate contract research organization (CRO) to conduct valuable research using reliable data. The food and Drug Administration (FDA) approved 50 novel drugs in 2021. 36 are small molecules which is 72% of the total approval of pharmaceutical drugs by the FDA.

Segmentation by Product Type

  • Small Molecules
  • Biologics

Insights by Stage of development

a) Among stages of development, the clinical segment reported a major share of around 64.13% in 2021. The clinical segment is estimated to be higher because, according to World Health Organization (WHO), approximately 47,689 clinical trials are in Phase I. The high number of clinical trials in phase 1 is highly outsourced. In outsourcing well-established data about patient recruitment, activities of clinical trials related to phase 1 and other procedures such as analysis and documentation are the easy thing done in the phase.
b) Phase 1 clinical trials required more than USD 30 million in capital investment. Compounds in oncology, respiratory diseases, and other therapeutic areas require a lot of money. Around 70% of drugs move from Phase I to the next phase states by US FDA.
c) Phase II can last for several years; as per the WHO, around 88,530 compounds in phase 2 clinical trials till 2022. As per US FDA, approximately 33% of new drugs are moved from phase II to the next.
d) The number of subjects usually ranges from hundreds to about 3,000. If the FDA agrees that the study results are positive, the FDA will approve the experimental drug or equipment. As per the WHO, around 68,999 drugs came to phase III till 2022. In this phase, doctors, physicians, or professionals do not know whether the treatment is better, so random participants are picked up to get the approval for new treatment and sent into the next phase. This procedure is often done in many places across the region/world at the same time to analyze the efficacy of drugs in different geography and demography.

Segmentation by Stage of Development

  • Clinical
  • Non-Clinical

Insights by Size of Company

a) Among the size of the company, the small & mid-sized companies segment reported a major share of around 57.54% in 2021. The small & mid-sized companies market segment is estimated to be higher because, in 2019, the emerging therapeutic companies (ETC) were responsible for 73% (5,067 of 6,984) of global industrial, and pharmaceutical projects at all clinical stages, either alone or in collaboration with partners, with the rest being carried out by large companies.
b) SMEs will account for 71%, 76%, 68%, and 62% of Phase I, II, III, and new drug applications, respectively, compared to large companies. 45% of all clinical ETC pipeline projects are carried out in collaboration with other partners. Oncology is the main disease focus of these SME clinical projects.
c) In 2018, the Market researcher identified that 74 small pharmaceutical companies have total sales of $159 billion and 446 pharmaceuticals drugs in their R&D pipeline, 9 medium-sized companies with sales of $50 billion and 181 products, and sales of $139 billion in the R& D pipeline.
d) A 2017 BIO industry analysis shows that small biotechnology companies are responsible for 70% of all bio pharmacy clinical trials worldwide, representing 6,679 programs, 43% of which partner with other companies. It was carried out. Large companies conducted the remaining 30% of these clinical trials.

Segmentation by Company Size

  • Small & Mid-Sized Companies
  • Large Companies

Insights by Therapy Areas

a) Among therapy areas, the oncology segment reported a major share of around 30.71% in 2021. The oncology segments are estimated to be higher because there are 19.3 million new cancer instances and approximately 10 million fatalities worldwide in 2020, accounting for nearly one out of every six deaths as per Globocan 2020 report.
b) Oncology is one of the most dominant therapy areas for industry and non-industry-sponsored clinical trials. The rising prevalence of cancer conditions significantly contributed to oncology therapeutic area clinical trials. Changing the paradigm for testing cancer treatment in the world increased the global efforts toward generating evidence for oncology clinical trials.
c) In 2019 only around 30 FDA approvals were registered for chemotherapeutic drugs. In the US, about 361,628 clinical trials have been reported only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.
d) Global spending on anticancer medications climbed by 14.3% in 2020, reaching $164 billion. Spending is expected to reach $269 billion by 2025. The high prices of novel anticancer medicines drive much of this growth. The direct and indirect expenses of oncological treatments severely affect patients' treatment success and financial well-being worldwide.
e) In the US, around 361,628 clinical trials registered only for cancer in the past 20 years. Cancer clinical trial drug development activities increased significantly, leading to increased clinical trial volume.

Segmentation by Therapy Area

  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Musculoskeletal Disorders
  • Central Nervous System Disorders
  • Gastrointestinal Disorders
  • Other Therapy Areas


The North America region reported a significant share of around 36.23% in 2021. The North America region is estimated to be higher because considerable investment by companies in R&D to strengthen the pipeline for chronic diseases is projected to boost the launch of novel therapeutics in North America. North America witnesses prominent start-up CROs working in the pharmaceutical R&D outsourcing market. The region also saw collaborations and partnerships among the pharmaceutical ecosystem's stakeholders.

Segmentation by Geography

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • APAC
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Turkey
  • UAE


Vendors in the pharma R&D outsourcing market compete based on the wide range of services offered, quality, and scale-up development of pharmaceuticals. The market is so competitive that vendors aim to implement different strategies to maintain their competitive advantage over other vendors. The market players focus on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their market share. There are around 33 vendors in the pharmaceutical R&D outsourcing market, including key players and other prominent players.

Key Vendors

  • Charles River Laboratories
  • ICON
  • Labcorp Drug Development
  • Medpace
  • Parexel International Corporation
  • Syneos Health
  • Thermo Fisher Scientific
  • Wuxi AppTec
  • Lonza
  • Boehringer Ingelheim
  • Samsung Biologics

Other Prominent Vendors

  • AbbVie
  • Advanced Clinical
  • BioAnalytix
  • Asymchem
  • Alcami
  • Bavarian Nordic
  • Catalent
  • Curia Global
  • ChemPartner
  • CMED
  • Criterium
  • Cromos Pharma
  • Evotec
  • Jubilant HollisterStier
  • KBI Biopharma
  • KCR S.A.
  • Kemwell Biopharma
  • Mesned Pharma Consult Center
  • Midas Pharma
  • Medelis
  • Merck KGaA
  • OCT Clinical
  • Pharmaceutics International
  • ProTrials Research
  • QPS
  • Singota Solutions
  • Sofpromed
  • Sanofi
  • Taros chemicals
  • Veristat
  • Worldwide Clinical Trials
  • WuXi Biologics
  • Wacker Biotech B.V


1. How big is the pharmaceutical R&D outsourcing market?
2. What is the growth rate of the global pharmaceutical R&D outsourcing market?
3. Who are the key players in the global pharma R&D outsourcing market?
4. Which geographical region leads in the pharma R&D outsourcing market?
5. What are the growth factors in the global pharmaceutical R&D outsourcing market?

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of the Study
4.3.1 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.1.1 Drug Development
7.2 Pharmaceuticals and the Need for Outsourcing R&D Activities
7.2.1 Contract Research Organizations and Contract Development & Manufacturing Organizations
8 Premium Insights
8.1 Market Overview
8.1.1 Pharmaceutical R&D Outsourcing Market Scenario
8.1.2 Insight by Market Dynamics
8.2 Pharmaceutical R&D Outsourcing Market Segmentations
8.2.1 Insights by Product
8.2.2 Insights by Stage of Development
8.2.3 Insights by Company Size
8.2.4 Insights by Therapy Area
8.2.5 Insights by Geography
8.2.6 Vendor Landscape
9 Market Opportunities & Trends
9.1 Paradigm Shift Toward Virtual Clinical Trials
9.2 Emergence of Ai in Drug Discovery & Development
9.3 Rising Venture Capitalist Investments in the Life Sciences/Biotech Industry
9.4 Surge in Usage of Cloud-Based Computing & Related Software Platforms in R&D
10 Market Growth Enablers
10.1 Increasing Collaborations and Partnerships Among Cros and Other Stakeholders
10.2 Increasing Target Patient Demographics
10.3 Surge in Outsourcing of Clinical Trials
11 Market Restraints
11.1 High Cost & Low Success Rate of Pharmaceutical R&D
11.2 Lack of Transparency & Specificity, Long Timelines, & Changing Practices
11.3 Geographical Location and Crucial Regulatory Aspects
12 Market Landscape
12.1 Market Overview
12.2 Market Size & Forecast
12.2.1 Insights by Geography
12.2.2 Insights by Stage of Development
12.2.3 Insights by Product
12.2.4 Insights by Company Size
12.2.5 Insights by Therapy Area
12.3 Five Forces Analysis
12.3.1 Threat of New Entrants
12.3.2 Bargaining Power of Suppliers
12.3.3 Bargaining Power of Buyers
12.3.4 Threat of Substitutes
12.3.5 Competitive Rivalry
13 Stage of Development
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Clinical
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 Market by Geography
13.4 Non-Clinical
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 Market by Geography
14 Product
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Small Molecules
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Market by Geography
14.4 Biologics
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 Market by Geography
15 Company Size
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Small & Mid-Sized Companies
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.3.3 Market by Geography
15.4 Large Companies
15.4.1 Market Overview
15.4.2 Market Size & Forecast
15.4.3 Market by Geography
16 Therapy Area
16.1 Market Snapshot & Growth Engine
16.2 Market Overview
16.3 Oncology
16.3.1 Market Overview
16.3.2 Market Size & Forecast
16.3.3 Market by Geography
16.4 Cardiovascular Diseases
16.4.1 Market Overview
16.4.2 Market Size & Forecast
16.4.3 Market by Geography
16.5 Infectious Diseases
16.5.1 Market Overview
16.5.2 Market Size & Forecast
16.5.3 Market by Geography
16.6 Musculoskeletal Disorders
16.6.1 Market Overview
16.6.2 Market Size & Forecast
16.6.3 Market by Geography
16.7 Central Nervous System Disorders
16.7.1 Market Overview
16.7.2 Market Size & Forecast
16.7.3 Market by Geography
16.8 Gastrointestinal Disorders
16.8.1 Market Overview
16.8.2 Market Size & Forecast
16.8.3 Market by Geography
16.9 Other Therapy Areas
16.9.1 Market Overview
16.9.2 Market Size & Forecast
16.9.3 Market by Geography
17 Geography
17.1 Market Snapshot & Growth Engine
17.2 Geographic Overview
18 North America
18.1 Market Overview
18.2 Market Size & Forecast
18.2.1 North America: Stage of Development
18.2.2 North America: Product Segmentation
18.2.3 North America: Company Size Segmentation
18.2.4 North America: Therapy Area Segmentation
18.3 Key Countries
18.3.1 Us: Market Size & Forecast
18.3.2 Canada: Market Size & Forecast
19 Europe
19.1 Market Overview
19.2 Market Size & Forecast
19.2.1 Europe: Stage of Development
19.2.2 Europe: Product Segmentation
19.2.3 Europe: Company Size Segmentation
19.2.4 Europe: Therapy Area Segmentation
19.3 Key Countries
19.3.1 Germany: Market Size & Forecast
19.3.2 Uk: Market Size & Forecast
19.3.3 France: Market Size & Forecast
19.3.4 Spain: Market Size & Forecast
19.3.5 Italy: Market Size & Forecast
20 Apac
20.1 Market Overview
20.2 Market Size & Forecast
20.2.1 Apac: Stage of Development
20.2.2 Apac: Product Segmentation
20.2.3 Apac: Company Size Segmentation
20.2.4 Apac: Therapy Area Segmentation
20.3 Key Countries
20.3.1 China: Market Size & Forecast
20.3.2 Japan: Market Size & Forecast
20.3.3 India: Market Size & Forecast
20.3.4 Australia: Market Size & Forecast
20.3.5 South Korea: Market Size & Forecast
21 Latin America
21.1 Market Overview
21.2 Market Size & Forecast
21.2.1 Latin America: Stage of Development
21.2.2 Latin America: Product Segmentation
21.2.3 Latin America: Company Size Segmentation
21.2.4 Latin America: Therapy Area Segmentation
21.3 Key Countries
21.3.1 Brazil: Market Size & Forecast
21.3.2 Mexico: Market Size & Forecast
21.3.3 Argentina: Market Size & Forecast
22 Middle East & Africa
22.1 Market Overview
22.2 Market Size & Forecast
22.2.1 Middle East & Africa: Stage of Development
22.2.2 Middle East & Africa: Product Segmentation
22.2.3 Middle East & Africa: Company Size Segmentation
22.2.4 Middle East & Africa: Therapy Area Segmentation
22.3 Key Countries
22.3.1 Turkey: Market Size & Forecast
22.3.2 Saudi Arabia: Market Size & Forecast
22.3.3 South Africa: Market Size & Forecast
22.3.4 Uae: Market Size & Forecast
23 Competitive Landscape
23.1 Competition Overview
23.2 Market Share Analysis
24 Key Company Profiles
24.1 Charles River Laboratories
24.1.1 Business Overview
24.1.2 Charles River Laboratories in the Pharmaceutical R&D Outsourcing Market
24.1.3 Service Offerings
24.1.4 Key Strategies
24.1.5 Key Strengths
24.1.6 Key Opportunities
24.2 Icon
24.2.1 Business Overview
24.2.2 Icon in the Pharmaceutical R&D Outsourcing Market
24.2.3 Service Offerings
24.2.4 Key Strategies
24.2.5 Key Strengths
24.2.6 Key Opportunities
24.3 Iqvia
24.3.1 Business Overview
24.3.2 Iqvia in the Pharmaceutical R&D Outsourcing Market
24.3.3 Service Offerings
24.3.4 Key Strategies
24.3.5 Key Strengths
24.3.6 Key Opportunities
24.4 Labcorp Drug Development
24.4.1 Business Overview
24.4.2 Labcorp Drug Development in the Pharmaceutical R&D Outsourcing Market
24.4.3 Service Offerings
24.4.4 Key Strategies
24.4.5 Key Strengths
24.4.6 Key Opportunities
24.5 Medpace
24.5.1 Business Overview
24.5.2 Medpace in the Pharmaceutical R&D Outsourcing Market
24.5.3 Service Offerings
24.5.4 Key Strategies
24.5.5 Key Strengths
24.5.6 Key Opportunities
24.6 Parexel International Corporation
24.6.1 Business Overview
24.6.2 Parexel International in the Pharmaceutical R&D Outsourcing Market
24.6.3 Service Offerings
24.6.4 Key Strategies
24.6.5 Key Strengths
24.6.6 Key Opportunities
24.7 Syneos Health
24.7.1 Business Overview
24.7.2 Syneos Health in the Pharmaceutical R&D Outsourcing Market
24.7.3 Service Offerings
24.7.4 Key Strategies
24.7.5 Key Strengths
24.7.6 Key Opportunities
24.8 Thermo Fisher Scientific
24.8.1 Business Overview
24.8.2 Thermo Fisher Scientific in the Pharmaceutical R&D Outsourcing Market
24.8.3 Service Offerings
24.8.4 Key Strategies
24.8.5 Key Strengths
24.8.6 Key Opportunities
24.9 Wuxi Apptec
24.9.1 Business Overview
24.9.2 Wuxi Apptec in the Pharmaceutical R&D Outsourcing Market
24.9.3 Service Offerings
24.9.4 Key Strategies
24.9.5 Key Strengths
24.9.6 Key Opportunities
24.10 Lonza
24.10.1 Business Overview
24.10.2 Lonza in the Pharmaceutical R&D Outsourcing Market
24.10.3 Service Offerings
24.10.4 Key Strategies
24.10.5 Key Strengths
24.10.6 Key Opportunities
24.11 Boehringer Ingelheim
24.11.1 Business Overview
24.11.2 Boehringer Ingelheim in the Pharmaceutical R&D Outsourcing Market
24.11.3 Service Offerings
24.11.4 Key Strategies
24.11.5 Key Strengths
24.11.6 Key Opportunities
24.12 Samsung Biologics
24.12.1 Business Overview
24.12.2 Samsung Biologics in the Pharmaceutical R&D Outsourcing Market
24.12.3 Service Offerings
24.12.4 Key Strategies
24.12.5 Key Strengths
24.12.6 Key Opportunities
25 Other Prominent Vendors
25.1 Abbvie
25.1.1 Business Overview
25.1.2 Service Offerings
25.2 Advanced Clinical
25.2.1 Business Overview
25.2.2 Product Offerings
25.3 Bioanalytix
25.3.1 Business Overview
25.3.2 Product Offerings
25.4 Asymchem
25.4.1 Business Overview
25.4.2 Service Offerings
25.5 Alcami
25.5.1 Business Overview
25.5.2 Service Offerings
25.6 Bavarian Nordic
25.6.1 Business Overview
25.6.2 Service Offerings
25.7 Catalent
25.7.1 Business Overview
25.7.2 Service Offerings
25.8 Curia Global
25.8.1 Business Overview
25.8.2 Service Offerings
25.9 Chempartner
25.9.1 Business Overview
25.9.2 Service Offerings
25.10 Cmed
25.10.1 Business Overview
25.10.2 Product Offerings
25.11 Criterium
25.11.1 Business Overview
25.11.2 Product Offerings
25.12 Cromos Pharma
25.12.1 Business Overview
25.12.2 Product Offerings
25.13 Evotec
25.13.1 Business Overview
25.13.2 Service Offerings
25.14 Jubilant Hollisterstier
25.14.1 Business Overview
25.14.2 Service Offerings
25.15 Kbi Biopharma
25.15.1 Business Overview
25.15.2 Service Offerings
25.16 Kcr S.A.
25.16.1 Business Overview
25.16.2 Product Offerings
25.17 Kemwell Biopharma
25.17.1 Business Overview
25.17.2 Service Offerings
25.18 Mesned Pharma Consult Center (Mpcc)
25.18.1 Business Overview
25.18.2 Service Offerings
25.19 Midas Pharma
25.19.1 Business Overview
25.19.2 Service Offerings
25.20 Medelis
25.20.1 Business Overview
25.20.2 Product Offerings
25.21 Merck Kgaa
25.21.1 Business Overview
25.21.2 Service Offerings
25.22 Oct Clinical
25.22.1 Business Overview
25.22.2 Product Offerings
25.23 Pharmaceutics International
25.23.1 Business Overview
25.23.2 Service Offerings
25.24 Protrials Research
25.24.1 Business Overview
25.24.2 Product Offerings
25.25 Prometrika
25.25.1 Business Overview
25.25.2 Product Offerings
25.26 Qps
25.26.1 Business Overview
25.26.2 Product Offerings
25.27 Singota Solutions
25.27.1 Business Overview
25.27.2 Service Offerings
25.28 Sofpromed
25.28.1 Business Overview
25.28.2 Service Offerings
25.29 Sanofi
25.29.1 Business Overview
25.29.2 Service Offerings
25.30 Taros Chemicals
25.30.1 Business Overview
25.30.2 Service Offerings
25.31 Veristat
25.31.1 Business Overview
25.31.2 Product Offerings
25.32 Worldwide Clinical Trials
25.32.1 Business Overview
25.32.2 Product Offerings
25.33 Wuxi Biologics
25.33.1 Business Overview
25.33.2 Service Offerings
25.34 Wacker Biotech B.V
25.34.1 Business Overview
25.34.2 Service Offerings
26 Report Summary
26.1 Key Takeaways
26.2 Strategic Recommendations
27 Quantitative Summary
27.1 Market by Stage of Development
27.1.1 North America: Stage of Development Segmentation
27.1.2 Europe: Stage of Development Segmentation
27.1.3 Apac: Stage of Development Segmentation
27.1.4 Latin America: Stage of Development Segmentation
27.1.5 Middle East & Africa: Stage of Development Segmentation
27.2 Market by Product
27.2.1 North America: Product Segmentation
27.2.2 Europe: Product Segmentation
27.2.3 Apac: Product Segmentation
27.2.4 Latin America: Product Segmentation
27.2.5 Middle East & Africa: Product Segmentation
27.3 Market by Company Size
27.3.1 North America: Company Size Segmentation
27.3.2 Europe: Company Size Segmentation
27.3.3 Apac: Company Size Segmentation
27.3.4 Latin America: Company Size Segmentation
27.3.5 Middle East & Africa: Company Size Segmentation
27.4 Market by Therapy Area
27.4.1 North America: Therapy Area Segmentation
27.4.2 Europe: Therapy Area Segmentation
27.4.3 Apac: Therapy Area Segmentation
27.4.4 Latin America: Therapy Area Segmentation
27.4.5 Middle East & Africa: Therapy Area Segmentation
27.5 Market by Geography
27.5.1 Clinical: Geography Segmentation
27.5.2 Non-Clinical: Geography Segmentation
27.5.3 Small Molecules: Geography Segmentation
27.5.4 Biologics: Geography Segmentation
27.5.5 Small & Mid-Sized Companies: Geography Segmentation
27.5.6 Large Companies: Geography Segmentation
27.5.7 Oncology: Geography Segmentation
27.5.8 Cardiovascular Diseases: Geography Segmentation
27.5.9 Infectious Diseases: Geography Segmentation
27.5.10 Musculoskeletal Disorders: Geography Segmentation
27.5.11 Central Nervous System Disorders: Geography Segmentation
27.5.12 Gastrointestinal Disorders: Geography Segmentation
27.5.13 Other Therapy Areas: Geography Segmentation
28 Appendix
28.1 Abbreviations

Companies Mentioned

  • Charles River Laboratories
  • ICON
  • Labcorp Drug Development
  • Medpace
  • Parexel International Corporation
  • Syneos Health
  • Thermo Fisher Scientific
  • Wuxi AppTec
  • Lonza
  • Boehringer Ingelheim
  • Samsung Biologics
  • AbbVie
  • Advanced Clinical
  • BioAnalytix
  • Asymchem
  • Alcami
  • Bavarian Nordic
  • Catalent
  • Curia Global
  • ChemPartner
  • CMED
  • Criterium
  • Cromos Pharma
  • Evotec
  • Jubilant HollisterStier
  • KBI Biopharma
  • KCR S.A.
  • Kemwell Biopharma
  • Mesned Pharma Consult Center
  • Midas Pharma
  • Medelis
  • Merck KGaA
  • OCT Clinical
  • Pharmaceutics International
  • ProTrials Research
  • QPS
  • Singota Solutions
  • Sofpromed
  • Sanofi
  • Taros chemicals
  • Veristat
  • Worldwide Clinical Trials
  • WuXi Biologics
  • Wacker Biotech B.V


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.